Brief: ADMA Biologics Says Q4 Revenue Rose 193% To $11.9 Million

ADMA Biologics

09/01/2020 12:52

Jan 9 (Reuters) - ADMA Biologics Inc  ADMA.O :
    * ADMA BIOLOGICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND
FULL
YEAR 2019 REVENUES AND PROVIDES 2020 STRATEGIC OUTLOOK
    * Q4 REVENUE ROSE 193 PERCENT TO $11.9 MILLION
    * Q4 REVENUE ESTIMATE $8.6 MILLION -- REFINITIV IBES DATA
    * COMMERCIAL LAUNCHES FOR BIVIGAM AND ASCENIV PROGRESSING IN
LINE
WITH EXPECTATIONS
    * ADMA BIOLOGICS -  2020 PRIORITIES INCLUDE EXPANDING
THROUGHPUT
CAPACITY AT MANUFACTURING FACILITY
    * ADMA BIOLOGICS -  2020 PRIORITIES INCLUDE ENHANCING
CONTROL OVER
SUPPLY-CHAIN FOR COMMERCIAL PRODUCTS
    * ADMA BIOLOGICS -  2020 PRIORITIES INCLUDE SECURING NEW
CONTRACT
MANUFACTURING SUPPLY AGREEMENTS, BUILDING, OPENING NEW PLASMA
COLLECTION CENTERS

Source text for Eikon:  ID:nGNX2ftmjh 
Further company coverage:  ADMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))